



The Chinese Pharmaceutical Market to 2024

Commercial & Strategic Developments in the Chinese Pharmaceutical Market to 2024



GMRData.com

Contents

1. Executive Summary

- 1.1. Chinese Pharmaceutical Market Review
- 1.2. Chapter Breakdown
- 1.3. Research and Analysis Methods

2. Drivers & Restraints of Chinese Pharmaceutical Market

- 2.1 An Ageing Population will drive pharmaceutical market growth in China
- 2.2 Increase in Chinese urbanisation
- 2.3 Increase in Healthcare expenditure will increase drug demand in China
- 2.4 Government policies and changing environment for MNCs in China
- 2.5 Increased demand for improved drug quality
- 2.6 Healthcare Reform in China
- 2.7 Path to privatization of Chinese healthcare
- 2.8 Consolidation of the pharmaceutical distribution industry in China
- 2.9 Increase in lifestyle related diseases
- 2.10 Biotechnology Market: The Strategic Industry for China
- 2.11 Focus on GMP leads to Quality and Compliance reforms
- 2.12 Government led initiatives to attract foreign players
- 2.13 Talent Pool Availability
- 2.14 Increased Outsourcing of Drug Discovery boosting the Chinese CRO Market
- 2.15 Regulatory Environment
 - 2.15.1 Drug filing
 - 2.15.2 Advertisements
 - 2.15.3 Drugs Pricing & Reimbursement
- 2.16 Traditional Chinese Medicine

3. China Pharmaceutical Market Forecast

- 3.1 Chinese Pharmaceutical Market; Pharmaceutical Sales (OTC and Prescription market)
 - 3.1.1 Chinese pharmaceutical sales market Forecast 2008-2024
 - 3.1.2 China Pharmaceutical Sales Market by Generic and Patented Drug Sales
 - 3.1.3 Generic Drugs Market in China
- 3.2 The Chinese Patented Drugs Market
- 3.3 China Pharmaceutical Sales Market by Prescription and OTC Drug Sales
 - 3.3.1 Prescription Drug Market in China
 - 3.3.2 Over-the-Counter Drugs Market in China

4. The Chinese Medical Device Market

- 4.1 Overview of the Medical Device Market in China
- 4.2 China Medical Devices Market: Diagnostic Imaging Segment
- 4.3 China Medical Devices Market: Patient Aids Segment
- 4.4 China Medical Devices Market: Consumables Segment
- 4.5 The China Medical Devices Market: Dental Segment
- 4.6 China Medical Devices Market: Orthopaedic Segment
- 4.7 Challenges & Opportunities in the Medical devices market
 - 4.7.1 Opportunities
 - 4.7.2 Challenges
- 4.8 China Medical Devices Market: Players Landscape
 - 4.8.1 Multinational Corporations in the Chinese Medical devices market
 - 4.8.1.1 General Electric Healthcare
 - 4.8.1.1 Medtronic, Inc.
 - 4.8.1.2 Zimmer - Zimmer Holdings, Inc.

- 4.8.1.3 Stryker Corporation
- 4.8.1.4 Siemens Healthcare
- 4.8.1.5 Johnson & Johnson
- 4.8.1.6 Philips Healthcare (Suzhou) Co., Ltd
- 4.9 Key Domestic companies in the Chinese Medical devices market
 - 4.9.1 Weigao group
 - 4.9.2 Mindray Medical International Limited
 - 4.9.3 MicroPort Scientific Corporation
 - 4.9.4 Biosensors International Group, Ltd

5. The Chinese API Market

- 5.1 API Overview
 - 5.1.1 Global API Market
 - 5.1.1.1 APAC API Market
 - 5.1.1.2 The Chinese API Market
- 5.2 Major Growth Drivers for the Chinese API Market
- 5.3 Key Challenges
- 5.4 China API Market: Players Landscape
 - 5.4.1 Major Chinese API Manufacturers
 - 5.4.1.1 Zhejiang Hisun Pharmaceutical Co. Ltd
 - 5.4.1.2 Jiangsu Hengrui Medicine Co., Ltd
 - 5.4.1.3 CSPC Pharmaceutical Group Limited
 - 5.4.1.4 Shandong Xinhua Pharmaceutical Company Limited
 - 5.4.1.5 Shanghai Pharma Holding Company Limited
 - 5.4.1.6 North China Pharmaceutical Group Corp.

6. Key Chinese Therapeutic Markets

- 6.1 Cardiovascular Diseases

6.1.1 Chinese Cardiovascular Disease treatments market forecast 2014-2024

6.2 Infectious Diseases

6.2.1 Chinese Infectious Disease treatments market forecast 2014-2024

6.3 Oncology

6.3.1 Chinese Oncology treatments market forecast 2014-2024

6.4 Nervous System

6.4.1 The Chinese Nervous System market forecast 2014-2024

6.5 Alimentary Tract & Metabolism

6.5.1 The Chinese Alimentary Tract & Metabolism treatments market forecast 2014-2024

7. Major Players

7.1 Pfizer

7.2. Bayer

7.3. Sanofi-Aventis

7.4. AstraZeneca

7.5. Roche

7.6. Merck and Co.

7.7. Novartis

7.8. GSK

7.9. Novo Nordisk (Novo Nordisk (China) Pharmaceutical Co., Ltd.)

8. Expert Opinion

8.1 Dr Cezary Statuch – Vice President Bristol-Myers Squibb, China

8.2 Dr Eugene Buff – Primary Care Innovation Consulting & UsTech Discovery LLC

List of Tables

Table 2.1.1: Percentage of Chinese population aged 60 and over / 65 and over in 2000, 2011 & 2016

Table 2.1.2: Health spending in China, India and the US, 2009 & 2011 (\$/p/a & percentage change)

Table 2.1.3: Total Health Expenditure (as % of GDP); Selected Countries 2004 to 2011

Table 2.1.4: Life expectancy; Selected Countries 2004 to 2011

Table 2.2.1 Medical Coverage for Rural / Urban inhabitants in China 2006 / 2009 (million people)

Table 2.2.2: Major cities in China by population (2011)

Table 2.3.1 China's Health Care Expenditure Per Capita 2003-2011

Table 2.6.1: Key New Drugs on the 2012 Essential Drugs List

Table 2.8.1: Total Revenue of Key Chinese Pharmaceutical Distribution Companies, 2012 (\$/bn)

Table 2.9.1: Number of Patients with Diabetes in China

Table 2.15.3.1 China healthcare payment source breakdown 2000, 2005 & 2010 (%)

Table 3.1.1.1: China Pharmaceutical Sales Market Size: 2008-2013 (\$bn)

Table 3.1.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 (\$bn)

Table 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013

Table 3.1.3.2: China's Generic Drug Sales Market Forecast 2014-2024 (\$bn)

Table 3.2.1: China Parented Drug Sales Market Size: 2008-2013

Table 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 (\$bn)

Table 3.3.1.1: China Prescription Drugs Sales Market Size: 2008-2013

Table 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024

Table 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013

Table 3.3.2.2 China's OTC Drug Sales Percentage 2013

Table 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024

Table 4.a: The Chinese Medical Devices Market Forecast 2014 -2024, by device type (\$/bn)

Table 4.b: Key Device Segments CAGR 2014-2024 (%)

Table 4.c: Estimated China Medical Devices Market Share for Selected Segments 2014, 2019 and 2024 (%)

Table 4.1.1: China Medical Devices Market Size: 2008-2013

Table 4.1.2: China Medical Devices Export Market 2009-2011 (\$/bn)

Table 4.1.3: China Medical Devices Import Market

Table 4.1.4: China Medical Devices Market Forecast 2014-2024 (\$bn)

Table 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013 (\$/bn)

Table 4.2.2: China Medical Devices Market: Diagnostic Imaging Segment Forecast 2014-2024 (\$/bn)

Table 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 (\$/bn)

Table 4.3.2: China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 (\$/bn)

Table 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013 (\$/bn)

Table 4.4.2: The Chinese Medical Devices Market: Consumables Segment Forecast 2014-2024 (\$ bn)

Table 4.5.1: China Medical Devices Market: Dental Segment 2008-2013

Table 4.5.2: China Medical Devices Market: Dental Segment Forecast 2014-2024 (\$m)

Table 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013

Table 4.6.2: China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 (\$m)

Table 5.1: China API Market Forecast 2014 -2024, compared to Global API Market (\$ bn)

Table 5.1.1.: China API Market Size: 2009-2013

Table 5.1.2: China API Market Forecast 2014-2024 (\$bn)

Table 6.a: China Pharmaceutical Market by Therapeutic Areas 2014 -2024, (\$ bn)

Table 6.b: Key Therapeutic Areas CAGR 2014-2024 (%)

Table 6.c: Estimated China Pharmaceutical Market Share by Therapeutic Areas - 2014, 2019 and 2024 (%)

Table 6.1.1: Cardiovascular Disease Incidence China 2010 – 2013

Table 6.1.2: Deaths due to Cardiovascular Disease in India, China and Developed Markets

Table 6.1.3: China Pharmaceutical Market for Cardiovascular Disease, 2008 – 2013 (\$/bn)

Table 6.1.4: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 – 2024

Table 6.2.1: Infectious Disease Incidence 2010 – 2013

Table 6.2.2: Infectious Disease Mortality 2010 – 2013

Table 6.2.3: China Pharmaceutical Market for Systemic Anti-Infective, 2008 – 2013

Table 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 – 2024

Table 6.3.1: Cancer Incidence China 2010 – 2013

Table 6.3.2: Cancer Mortalities 2010 – 2013

Table 6.3.3: China Pharmaceutical Market for Oncology, 2008 – 2013

Table 6.3.4: China Pharmaceutical Market for Oncology: Forecast 2014 – 2024

Table 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 – 2013

Table 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 – 2024

Table 6.5.1: China Pharmaceutical Market for Metabolism, 2008 – 2013

Table 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 – 2024

List of Figures

Figure 2.1.1: China population growth trend 1950-2013

Figure 2.1.2: Projected comparison of China's population vs. other heavily populated countries 2016 (million people)

Figure 2.1.3: China's Age distribution: 2001 to 2011

Figure 2.1.4: Life expectancy in China

Figure 2.2.1: China's Rural and Urban population from 1990 to 2025 – Billion People

Figure 2.2.2: China's Urbanisation Rate 1990-2025 (%)

Figure 2.2.3: Per Capita Disposable Income

Figure 2.3.1: China GDP growth trend (2004 – 2012)

Figure 2.3.2: China's total health expenditure (as % of GDP): 2004 to 2011

Figure 2.3.3: China healthcare expenditure per capita growth trend (2003 – 2011)

Figure 2.6.1: China's 2009 health care reform – Healthcare package breakdown

Figure 2.8.1: Chinese pharmaceutical distribution sales: 2006 to 2012

Figure 2.9.1: Number of Patients with Diabetes in 2013 – Globally (million people)

Figure 2.13.1: China's talent pool in 2010- (in millions)

Figure 2.15.3.1: China healthcare payment source breakdown

Figure 3.1.1: China Pharmaceutical Sales Market Size: 2008-2013

Figure 3.1.2: China Pharmaceutical Sales Market Forecast 2014-2024 (\$bn)

Figure 3.1.3.1: China Generic Drug Sales Market Size: 2008-2013

Figure 3.1.3.2: China's Generic Drug Sales Market Forecast 2014-2024 (\$ bn)

Figure 3.2.1: China Patented Drug Sales Market Size: 2008-2013

Figure 3.2.2: China Patented Drug Sales Market Forecast 2014-2024 (\$ bn)

Figure 3.3.1.1: China Prescription Drug Sales Market Size: 2008-2013

Figure 3.3.1.2: China Prescription Drug Sales Market Size: 2014-2024

Figure 3.3.2.1: China OTC Drug Sales Market Size: 2008-2013

Figure 3.3.2.2 OTC drugs Channel Breakdown in China 2011

Figure 3.2.2.3: China OTC Drug Sales Market Size: 2014-2024

Figure 4.a: China Medical Devices Market Share for Selected Segments 2014

Figure 4.b: China Medical Devices Market Share for Selected Segments 2019

Figure 4.c: China Medical Devices Market Share for Selected Segments 2024

Figure 4.1.1: China Medical Devices Market Size: 2008-2013

Figure 4.1.2: China Medical Devices Market Forecast 2014-2024 (\$bn)

Figure 4.2.1: China Medical Devices Market: Diagnostic Imaging Segment 2008-2013

Figure 4.2.2: China Diagnostic Imaging devices breakdown by sub-segment, 2012 (%)

Figure 4.2.3: China Medical Devices Market: Diagnostics Segment Forecast 2014-2024 (\$bn)

Figure 4.3.1: China Medical Devices Market: Patient Aids Segment 2008-2013 (\$/bn)

Figure 4.3.2: 2012 Patient Aids devices breakdown by sub-segment 2012 (%)

Figure 4.3.3: China Medical Devices Market: Patient Aids Segment Forecast 2014-2024 (\$/bn)

Figure 4.4.1: China Medical Devices Market: Consumables Segment 2008-2013

Figure 4.4.2: 2012 Consumables devices breakdown by sub-segment

Figure 4.4.3: China Medical Devices Market: Consumables Segment Forecast 2014-2024 (\$ bn)

Figure 4.5.1: China Medical Devices Market: Dental Segment 2008-2013

Figure 4.5.2: 2012 Dental Devices breakdown by sub-segment, China, 2013

Figure 4.5.3: China Medical Devices Market: Dental Segment Forecast 2014-2024 (\$m)

Figure 4.6.1: China Medical Devices Market: Orthopaedic Segment 2008-2013

Figure 4.6.2: 2012 Orthopaedic Devices breakdown by sub-segment

Figure 4.6.3: China Medical Devices Market: Orthopaedic Segment Forecast 2014-2024 (\$m)

Figure 4.8.1.2.1: Medtronic 2012 Customer base breakdown by region

Figure 4.9.1.1: 2012 Customer base breakdown by segment

Figure 4.9.1.2: 2012 Sales revenue breakdown by region

Figure 4.9.1.3: Weigao Group Sales revenue breakdown by product segment 2012 (%)

Figure 4.9.2.1: 2012 Sales revenue breakdown by region

Figure 4.9.2.2: 2012 Sales revenue breakdown by product

Figure 4.9.3.1: 2012 Sales revenue breakdown by product (%)

Figure 4.9.4.1: 2012 Sales revenue breakdown by product (%)

Figure 5.1.1.1: Breakdown of API Manufacturing 2012

Figure 5.1.1.2.1: China API Market Size: 2009-2013

Figure 5.1.1.2.2: China API Market Breakdown 2013

Figure 5.1.1.2.3: China API Market Forecast 2014-2024 (\$bn)

Figure 6.a: China Pharmaceutical Market Share by Therapeutic Areas 2014

Figure 6.b: China Pharmaceutical Market Share by Therapeutic Areas 2019

Figure 6.c: China Pharmaceutical Market Share by Therapeutic Areas 2024

Figure 6.1.1: Cardiovascular Disease Incidence 2010 – 2013

Figure 6.1.2: China Pharmaceutical Market for Cardiovascular Disease, 2008 – 2013
(\$/bn)

Figure 6.1.3: China Pharmaceutical Market for Cardiovascular Disease: Forecast 2014 – 2024

Figure 6.2.1: Infectious Disease Incidence 2010 – 2013

Figure 6.2.2: Infectious Disease Mortality 2010 – 2013

Figure 6.2.3: Mortality as per Infectious Diseases, China 2012

Figure 6.2.4: China Pharmaceutical Market for Systemic Anti-Infective, 2008 – 2013

Figure 6.2.5: China Pharmaceutical Market for Systemic Anti-Infective: Forecast 2014 – 2024

Figure 6.3.1: Cancer Deaths in China / Hong Kong, 2011

Figure 6.3.2: China Pharmaceutical Market for Oncology, 2008 – 2013

Figure 6.3.3: China Pharmaceutical Market for Oncology: Forecast 2014 – 2024

Figure 6.4.1: China Pharmaceutical Market for Central Nervous System, 2008 – 2013

Figure 6.4.2: China Pharmaceutical Market for Central Nervous System: Forecast 2014 – 2024

Figure 6.5.1: China Pharmaceutical Market for Metabolism, 2008 – 2013

Figure 6.5.2: China Pharmaceutical Market for Metabolism: Forecast 2014 – 2024

Figure 7.9.1 Novo Nordisk's sales of diabetes products in China, 2012

Organisations mentioned in this Report

Abbott Laboratories and Takeda Pharmaceutical Co Ltd

Alcon

Alliance Boots GmbH

Amgen

Ascendancy Healthcare

Asclepis

AstraZeneca

Bayer Healthcare

BeiGene Ltd

Beijing Drug Administration

Beijing Montagne Medical Device Co., Ltd

Beijing Percil Instrument

Beijing University

BioMatrix

Biosensors Europe S.A.

Biosensors International Group, Ltd.

BMS

Boehringer Ingelheim

Celsion

Changzhou Kony Pharmaceutical Co., Ltd

Changzhou Pharmaceutical Incorporated

Charles River

China Resources Double Crane Pharmaceutical Co., Ltd

China Resources Sanjiu Pharmaceutical

China Shijiazhuang Pharmaceutical Group Co., Ltd (CSPC)

Ciba - Geigy Pharmaceutical Co., Ltd

Colgate-Palmolive Co

Concord Medical Services Holdings Limited

Covance

CSPC Huasheng Pharma

CSPC XNW Pharmaceutical Joint Stock Co., Ltd

CSPC Zhongrun Pharmaceutical Co. Ltd

Daiichi Sankyo

Dainippon Sumitomo Pharma

Eddingpharm

Eisai China Inc

Eisai Co., Ltd

FibroGen

Fudan University

GE Healthcare

GlaxoSmithKline

Grandhope Biotech

Guangzhou Pharma

Hangzhou East China Pharmaceutical Group

Hangzhou Optcla Medical Instrument

Hangzhou Tigermed Consulting

Harbin Pharmaceutical

Harbin Pharmaceutical Group Holding Co., Ltd

Hawley & Hazel (BVI) Co. Ltd.

Hisor

Hua Medicine Ltd

ICON

Innovation Centre China (ICC)

Ironwood Pharmaceuticals

Japan's Pharmaceuticals and Medical Devices Agency (PMDA)

Jiangsu Hengrui Medicine Co., Ltd

Johnson & Johnson

JOINN Laboratories

Jointown

Journal of Toxicology and Environmental Health

JW MedicalSystems Ltd

Kanghui Holdings

KangHui Medical

Kyowa Hakko Kirin Co.

LifeTech

Livzon Pharmaceutical Group Inc.

Medtronic

Merck & Co.

Merck Sharp & Dohme (China) Co. Ltd

MicroPort Scientific Corporation

Mindray

Nanjing MeiRui Pharma Co.

Nanjing Pharmaceutical Co.

Neptune Interlong Bio-Technique Co. Ltd. (NIBT)

NeuroVive Pharmaceutical AB

North China Pharmaceutical Group Corp (NCPC)

NovaMed

Novartis

Orchid Chemicals and Pharmaceuticals Limited

Peking University

Pfizer

Philips Electronics NV.

Philips Healthcare

Procter & Gamble Co.

ProteoTech

ProteoTech

Qianjin Pharmacy

Qidong Gaitianli Pharmaceutical

Quintiles

Roche

Sanofi- Aventis

SFDA

Shandong University

Shandong Weigao

Shandong Xinhua Pharmaceutical Company Limited

Shanghai Apex Electronics

Shanghai ChemPartner

Shanghai Institutes for Biological Sciences of Chinese Academy of Science

Shanghai Jiaotong University

Shanghai Jinhe Bio-Technology Co., Ltd

Shanghai Medical Optical Instrument

Shanghai New Hongqiao International Medical Center

Shanghai Pharmaceuticals

Shanghai Roche Pharmaceutical Co., Ltd.

Shanghai Zhongxi Sunve Pharmaceutical Co., Ltd.

ShangPharma

Shenzhen GSK-Neptunus Biologicals Co. Ltd

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd

Shijiazhuang Lerentang Pharmaceutical Co.

Siemens

Siemens Healthcare Diagnostics

Siemens Hearing Instrument (Suzhou)

Siemens Medical Solutions Diagnostics Ltd
Siemens Mindit Magnetic Resonance (SMMR)
Siemens Shanghai Medical Equipment (SSME)
Siemens X-Ray Vacuum Technology (Wuxi)
Sihuan Pharmaceutical Holdings
Sincere Pharmaceutical Group (SCR)
Sino Biological and Pharmaron
Sinopharm
Spectrum Dynamics Medical, Inc.
Stryker
Synthes
Takeda (China) International Trading Co., Ltd
Tasly Group
Tianjin Tasly Pharmaceutical
Topsun Science and Technology
Trauson Holdings
Tsinghua University
Unilever Group
FDA
Vital River
Weihai Medical Polymer Co., Ltd
Wuhan Dragonbio
WuXi Apptec
Wyeth
X-Body Biosciences

1.2 Chapter Breakdown

Chapter 1 is an executive summary.

Chapter 2 introduces the primary drivers & restraints affecting the Chinese pharmaceutical market; highlighting which factors will drive the pharmaceutical market in China.

Chapter 3 introduces the Chinese Pharmaceutical drugs market; describing how the generic, patented, prescription and OTC drugs market in China has developed across 2008-2013 and how the market will shape up across the forecast period of 2014-2024

Chapter 4 analyses the Chinese medical devices market in 2012-13 and forecasts market growth for 2014-2024. The chapter looks at domestic challenges and opportunities in the Chinese medical devices market.

Chapter 5 analyses the Chinese API drug market in 2012-13 and forecasts market growth for 2014-2024. With many strong domestic suppliers of API, how will the market fare over the next 10 years?

Chapter 6 analyses the major therapeutic areas; Cardiovascular Diseases, Infectious Diseases, Oncology, Nervous System and Alimentary Tract & Metabolism across 2012-13 and forecasts market growth for 2014-2024.

Chapter 7 discusses the leading companies operating in the Chinese pharmaceutical market, looking at those with currently marketed therapies, as well as those with promising R&D activities.

Chapter 8 Offers expert opinion from key pharmaceutical industry experts.

1.3 Research and Analysis Methods


This report harnesses primary and secondary research. This study provides world market forecasts and analyses of market drivers and restraints (including SWOT and forecast analyses) and principal developments. We also provide geographical breakdowns of the world market. Our analyses are original, benefiting from our consulting experts in industry, academia, medical practice and other roles. Our analysts also refer to industry data, company reports, news and trade articles, public health data, policy documents and other analysts' views. We conduct primary research by telephone interviews, correspondence or face-to-face discussions.

Our report contains quantitative and qualitative analytical content, covering the present and the future of healthcare markets. Although our report is a market-centered, we include medical and technical information. We include analyses of under-met market needs from the present looking forward. Our revenue forecasting assesses the magnitude and effects of driving and restraining forces, to determine annual growth and total sales across a series of years. We base our forecasts upon knowledge of financial performance, disease prevalence, product/technology characteristics and other factors, as well as data and opinions gathered from our primary and secondary research.

Products and vendors listed in this report are provided for reference and constitute neither a complete list, necessarily, nor an endorsement of any specific vendor or product. Also, in this report, only human cell products are considered.

Revenue figures in this report are for the respective world market, or market segment, unless stated otherwise. Tabulated revenue values for later years (2014 onwards) are whole-year predictions (January to December). Because of rounding, values may not add up exactly. Compound annual growth rate (CAGR) values are for 2014-2024. In this report, all revenue figures and market values are expressed in USD.

Figure 2.1.2 Projected comparison of China's population vs. other heavily populated countries 2016 (million people)



UN Statistics 2013

China, along with India, are the most populous nations globally; the UN estimate that by 2025 India will surpass China in terms of total population as China has adopted policies, such as the 'one child' policy, to curtail their increasing population. This 'one child' policy aimed at restraining population growth has resulted in the decrease of the younger population.

Due to the increasing elderly population and unmet medical needs, the Chinese government moved to implement healthcare reforms in 2009 with an investment of \$124bn over three years. Accessibility and affordability were highlighted as the two planks of reform, to be carried out in two phases. At the end of 2013 the Chinese government boasted of offering 95% of the population, up from 45% in 2006, a network of basic healthcare facilities and an expanded public medical insurance system.

GMR Data estimate that healthcare spending in China will increase to \$XXX by 2020 from \$357bn in 2011. This figure covers pharmaceuticals, medical products and consumer health. Health expenditure per capita in China has risen from \$191 in 2009 to \$xxx in 2011, which is significantly higher than India (\$44 in 2009 to \$xxx in 2011). While the US has the highest health spending per capita (\$7,990 in 2009 & \$xxx in 2011), the percentage growth rate (2009 vs. 2011) is higher in China compared to India and the US. The per capita spending on healthcare in Brazil, Russia and Indonesia is higher than China.

Table 2.1.2 Health spending in China, India and the US, 2009 & 2011 (\$/p/a & percentage change)

Country	2009	2011	% change
China	\$191	xxx	xxx
India	\$44	xxx	xxx
US	\$7,990	xxx	xxx

GMR Data 2014

In March 2013 the Chinese government announced its plan to increase its medical spending by 27% and increase their medicine reimbursement list from 205 to 520. Additional plans included increasing the medical insurance system to cover an additional 20 diseases such as cancer, leukemia and type-1 diabetes.

Table 2.1.3 Total Health Expenditure (as % of GDP); Selected Countries 2004 to 2011

	2004	2005	2006	2007	2008	2009	2010	2011
Brazil	7.13	xxx	xxx	xxx	xxx	xxx	xxx	xxx
China	4.75	xxx	xxx	xxx	xxx	xxx	xxx	xxx
India	4.50	xxx	xxx	xxx	xxx	xxx	xxx	xxx
Russia	5.19	xxx	xxx	xxx	xxx	xxx	xxx	xxx
United States	15.78	xxx	xxx	xxx	xxx	xxx	xxx	xxx

World Bank 2013

Compared to other developing countries, such as India, China has taken greater efforts in raising life expectancy, expanding general education and securing the health care of the total population. India allocates 1.27% of its gross domestic product to government spending on health care, China allots 2.7%.